<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100279'>Ulcerative colitis</z:hpo> (UC) is an inflammatory destructive disease of the large intestine occurred usually in the rectum and lower part of the colon as well as the entire colon </plain></SENT>
<SENT sid="1" pm="."><plain>Drug therapy is not the only choice for UC treatment and medical management should be as a comprehensive whole </plain></SENT>
<SENT sid="2" pm="."><plain>Azulfidine, <z:chebi fb="0" ids="6775">Asacol</z:chebi>, <z:chebi fb="0" ids="6775">Pentasa</z:chebi>, Dipentum, and <z:chebi fb="0" ids="6775">Rowasa</z:chebi> <z:hpo ids='HP_0000001'>all</z:hpo> contain <z:chebi fb="0" ids="6775">5-aminosalicylic acid</z:chebi> (<z:chebi fb="0" ids="6775">5-ASA</z:chebi>), which is the topical anti-inflammatory ingredient </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="6775">Pentasa</z:chebi> is more commonly used in treating Crohn's <z:mp ids='MP_0009482'>ileitis</z:mp> because <z:chebi fb="0" ids="6775">Pentasa</z:chebi> capsules release more <z:chebi fb="0" ids="6775">5-ASA</z:chebi> into the small intestine than <z:chebi fb="0" ids="6775">Asacol</z:chebi> tablets </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="6775">Pentasa</z:chebi> can also be used for treating mild to moderate UC </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="6775">Rowasa</z:chebi> enemas are safe and effective in treating ulcerative <z:mp ids='MP_0003305'>proctitis</z:mp> and <z:e sem="disease" ids="C0033252" disease_type="Disease or Syndrome" abbrv="">proctosigmoiditis</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The sulfa-free <z:chebi fb="0" ids="6775">5-ASA</z:chebi> agents (<z:chebi fb="0" ids="6775">Asacol</z:chebi>, <z:chebi fb="0" ids="6775">Pentasa</z:chebi>, Dipentum and <z:chebi fb="0" ids="6775">Rowasa</z:chebi>) have fewer side effects than sulfa-containing Azulfidine </plain></SENT>
<SENT sid="7" pm="."><plain>In UC patients with moderate to severe disease and in patients who failed to respond to <z:chebi fb="0" ids="6775">5-ASA</z:chebi> compounds, systemic (oral) <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> should be used </plain></SENT>
<SENT sid="8" pm="."><plain>Systemic <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> (<z:chebi fb="0" ids="8382">prednisone</z:chebi>, <z:chebi fb="2" ids="8378">prednisolone</z:chebi>, <z:chebi fb="11" ids="16962">cortisone</z:chebi>, etc.) are potent and fast-acting drugs for treating UC, Crohn's <z:mp ids='MP_0009482'>ileitis</z:mp> and <z:e sem="disease" ids="C0949272" disease_type="Disease or Syndrome" abbrv="">ileocolitis</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Systemic <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> are not effective in maintaining remission in patients with UC </plain></SENT>
<SENT sid="10" pm="."><plain>Serious side effects can result from prolonged <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> treatment </plain></SENT>
<SENT sid="11" pm="."><plain>To minimize side effects, <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> should be gradually reduced as soon as the disease remission is achieved </plain></SENT>
<SENT sid="12" pm="."><plain>In patients with <z:chebi fb="0" ids="50858">corticosteroid</z:chebi>-dependent or unresponsive to <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> treatment, surgery or immunomodulator is considered </plain></SENT>
<SENT sid="13" pm="."><plain>Immunomodulators used for treating severe UC include <z:chebi fb="2" ids="2948">azathioprine</z:chebi>/<z:chebi fb="1" ids="2208,50667">6-MP</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> </plain></SENT>
<SENT sid="14" pm="."><plain>Integrated traditional Chinese and Western medicine is safe and effective in maintaining remission in patients with UC </plain></SENT>
</text></document>